Dendritic Cell-Based Immunotherapy for Melanoma

Dendritic cell (DC)-based immunotherapy harnesses the unique capacity of DCs to capture, process and present tumour-associated antigens to T lymphocytes, thereby initiating potent adaptive immune responses against malignant melanoma. Approaches typically involve ex vivo generation of autologous DCs from peripheral blood monocytes, followed by antigen loading with peptides, tumour lysates or messenger RNA encoding neoantigens. Once reintroduced into patients, fully mature DCs migrate to lymphoid tissues to prime CD4+ helper and CD8+ cytotoxic T cells, leading to targeted tumour cell lysis. Clinical strategies have evolved through successive generations of DC vaccines, incorporating cytokine maturation cocktails, Toll-like receptor agonists and genetic modifications to enhance immunogenicity and lymph node homing. Adjuvant administration following surgical resection and integration with other immunomodulatory modalities has become a focal point, aiming to reduce recurrence and extend survival. Despite encouraging immunological readouts and favourable safety profiles, objective response rates remain modest, often limited by immunosuppressive elements within the tumour microenvironment and variable DC migratory efficiency. Recent efforts focus on combination regimens, novel antigen delivery platforms and personalised neoantigen selection to overcome tolerance mechanisms and improve durable clinical benefit in melanoma patients worldwide.

Research from Nature Portfolio

Recent studies have evaluated adjuvant intranodal administration of autologous CD1c+ conventional and plasmacytoid DCs loaded with melanoma antigens in resected stage IIIB/C patients. This randomized phase III trial demonstrated robust induction of antigen-specific T cell responses in over two thirds of treated individuals with an acceptable safety profile, although improvements in recurrence-free survival were not statistically significant. Functional analyses confirmed sustained immunogenicity, highlighting the need to refine antigen selection and optimise DC subset composition for enhanced clinical efficacy.

Dendritic Cell-Based Immunotherapy for Melanoma publication trend

The graph below shows the total number of articles in dendritic cell-based immunotherapy for melanoma across all publications each year (not limited to Nature Index journals).

Technical terms

Dendritic cell (DC): A professional antigen-presenting cell that captures and processes antigens before migrating to lymphoid organs to activate naive T cells.

Antigen loading: The ex vivo process of introducing tumour-associated peptides, proteins or nucleic acids into DCs for presentation to T lymphocytes.

Immune checkpoint inhibitors (ICIs): Therapeutic antibodies that block inhibitory pathways such as CTLA-4 and PD-1/PD-L1 to enhance T cell-mediated antitumour responses.

Tumour microenvironment (TME): The complex milieu surrounding cancer cells, including stromal components, immune cells and signalling molecules that can modulate therapeutic efficacy.

Adjuvant therapy: Treatment given after primary tumour resection to eradicate residual disease and reduce the risk of relapse.

References

1. Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial. Nature Communications (2024).
2. Enhancing Dendritic Cell Cancer Vaccination: The Synergy of Immune Checkpoint Inhibitors in Combined Therapies. International Journal of Molecular Sciences (2024).
3. Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial. Cancer Immunology, Immunotherapy (2020).
4. Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells—An Update. Pharmaceutics (2020).